The RAD 140 half life measured in the one human trial is about 44.7 hours. That one number is the whole human record on timing: the trial recorded no onset, and descriptions outside the published studies place the first noticeable changes within days in some accounts and only after several weeks in others.
A half-life is how long the plasma concentration of RAD140 takes to fall by half, and this one is the reason the trial administered the compound once daily. The women in that trial had advanced breast cancer, not the profile of a healthy man, so the figure may not carry over exactly; any figure quoted for testolone outside the trial record traces back to that single measurement, and since no second human study has reported the value, every question of schedule in this article turns on one number.
This article sets out the trial’s measurement, the consequences of such a half-life for once-daily administration and for clearance, and beside them what is described outside the trials about time of day, food, onset, and the pairing of RAD140 with MK-677 (ibutamoren), a growth hormone secretagogue. Drug-test detection windows, and any schedule for a reader to follow, stay out.
Why does one trial carry so much weight? Because of where RAD140 was tested. It is an orally administered selective androgen receptor modulator (SARM), a class named by analogy with the selective oestrogen receptor modulators, and the RAD 140 mechanism of action is that of a synthetic ligand of the androgen receptor, the protein inside cells that androgens act on. A compound on the usual licensing route has its pharmacokinetics, how it is absorbed, distributed and cleared over time, measured first in healthy volunteers; RAD140 went straight into oncology, as a candidate treatment for a tumour expressing that receptor, so its figures were measured in patients, and they carry the marks of that setting.
How the half-life was measured in the first human trial
The first-in-human phase 1 study of RAD140 (vosilasarm in the breast cancer trials) put its elimination half-life, the time plasma concentrations take to halve once absorption is complete and clearance dominates, at nearly two days, the value in hours that the figure below gives. At that earliest stage of testing in humans, safety and the handling of a compound count for more than efficacy, and the RAD 140 study set out to characterise safety, tolerability, the pharmacokinetic profile and the maximum tolerated dose (the highest dose whose toxicity a protocol accepts). The half-life came out of the third of those aims, pharmacokinetics.
The study opened with a dose escalation on a 3 + 3 design, which fills each dose level with a cohort of patients and adds a second cohort if toxicity appears before the next level opens, and a pharmacokinetic expansion cohort then brought the enrolment of women to the total the figure below shows. Of everything the study reported, the hours RAD-140 needed to fall to half its plasma concentration mattered most to the protocol, because that figure largely sets a dosing interval, and at nearly two days the interval is long for an orally administered agent.
[Figure 1. Where the 44.7-hour half-life came from. The only measured human half-life of RAD140 came from a phase 1 dose-escalation trial in 22 postmenopausal women with advanced breast cancer, given 50 to 150 mg once daily; the trial took its 44.7 hours as support for its own once-daily schedule.]
Was the half-life measured in healthy men or in cancer patients?
In cancer patients. The half-life of RAD140 comes from postmenopausal women, whose number the table below gives, with ER+/HER2- metastatic breast cancer (a tumour that carries oestrogen receptors, lacks HER2 amplification and has spread beyond the breast); 21 of them were androgen receptor (AR)-positive, and all had received several earlier lines of treatment.
Healthy adult male volunteers appear in one human study among this article’s sources, and it is of a different kind: a micro-dose excretion study, which administers a dose far below a pharmacological one and follows its appearance in urine, repeated several times with a small group of volunteers each time, as the table sets out. A design that samples urine rather than plasma yields elimination profiles and detection times, not a half-life. The trial’s value therefore belongs to the oncology population and its dose range, and it stands as the best human measure available rather than a figure established in healthy men.
The human data on RAD140 compared
Source
Who
Design
What it yields
Phase 1 trial
22 postmenopausal women with metastatic breast cancer
Dose escalation with once-daily dosing; plasma pharmacokinetics
Plasma half-life of 44.7 hours
Excretion studies
Adult male volunteers, five in each of six studies
Elimination profiles and detection times for the intact drug and six metabolites; no plasma half-life
Case report
One 24-year-old man
Single-patient report after 5 weeks of a product sold as RAD-140
Timeline of cholestatic liver injury, peak bilirubin 38.5 mg/dL
Is once a day enough given the half-life?
Enough for the trial, which gave each of its three dose levels once daily. The arithmetic is the RAD140 half-life’s: at nearly two days, much of one day’s dose is still circulating when the next arrives, so concentrations climb over the first days until absorption and clearance balance, which is steady state, and from then on they fluctuate less within each day than those of a compound with a short elimination half-life would. Dividing the daily dose was never examined; the published trial summary describes no schedule other than once-daily administration at every dose level.
The half-life (t 1/2 ) of 44.7 hours supported QD dosing.
Enrolment across the three once-daily dose levels was uneven: six women were on 50 mg, thirteen on 100 mg, and only three reached 150 mg, above the maximum tolerated dose of 100 mg a day. Toxicity, not any shortage of activity, closed the 150 mg level. Most of the human exposure therefore sits at the middle level, and the pharmacokinetic figure rests chiefly on 100 mg rather than on the range as a whole. These RAD140 doses went to patients with advanced cancer under hospital monitoring, and any reading of them has to start there.
The toxicity recorded across those levels falls into two groups of treatment-emergent adverse events, those arising during treatment whatever their cause. The hepatic group is the trial’s evidence on RAD140 liver toxicity: aspartate aminotransferase (AST) and its companion alanine aminotransferase (ALT), two enzymes measured in blood as markers of hepatocellular injury, rose more often than any other event, AST in the larger share of patients, and total bilirubin rose in a smaller share.
The gastrointestinal and nutritional group, vomiting, dehydration, decreased appetite and decreased body weight, each occurred as often as the bilirubin rise, so food consumption and weight were affected about as often as the clearance of bile; the figure below gives the share of patients for each event. Severity sharpens the picture: events of grade 3 or 4 affected 72.7% of patients, and among them AST and ALT elevations and hypophosphataemia (a low concentration of phosphate in blood) each reached 22.7%, which puts the two liver enzymes among the severe events as well.
[Figure 2. Most common adverse events in the trial. Among 22 women with advanced breast cancer given 50 to 150 mg of RAD140 daily in the phase 1 trial, rises in the liver enzymes AST and ALT were the most frequent adverse events of any cause, doses pooled.]
Signs of androgen receptor engagement in trial participants
Two blood markers served the trial as surrogates for engagement of the androgen receptor: serum sex hormone-binding globulin (SHBG) fell in every patient tested, and prostate-specific antigen (PSA) rose in most of those tested, as the figure below shows. Paired tumour biopsies taken before and during treatment then confirmed the engagement directly.
Clinical outcomes over the same period were modest, a clinical benefit rate of 18.2% at 24 weeks (the share of patients free of progression at that point) and a median progression-free survival of 2.3 months (the time by which half the patients had progressed or died). One thing the summary withholds matters for this article: it gives the share of patients whose markers moved, not the week when they moved, so onset in humans rests on these markers and on what is described outside the trials.
[Figure 3. Two blood markers of receptor engagement. In the phase 1 trial RAD140 engaged the androgen receptor: SHBG fell in all 18 women tested and PSA rose in 16 of 20, and paired tumour biopsies confirmed engagement; the trial did not report in which week the markers moved.]
When is the best time to take RAD140?
In descriptions beyond the trials, no single best time is named for RAD140. The patterns described are these:
one administration a day at whatever hour is easiest to keep, the pattern that comes up most often;
a morning hour, also widely described;
a move to the evening, or to shortly before sleep, after a sense of daytime tiredness;
the reverse move, back to the morning, after sleep was felt to worsen.
In those accounts the hour chosen makes little difference to anything but sleep and alertness, because the compound is held to persist over days rather than hours, and the practical questions that follow concern a late or missed administration and how a consistent hour can be kept when the time of waking varies. Such accounts of RAD 140 experience are individual and uncontrolled, collected and compared here rather than read as measurements; nothing in the human trial data identifies an optimal hour.
Does it matter what time of day RAD140 is taken?
Among the effects described outside the trials, the time of day at which RAD140 is administered is held to matter little, and the reason given is how long the compound is said to remain in circulation. In descriptions beyond the trials the differences that are named concern sleep, mood at a particular hour or the daytime tiredness described as RAD 140 lethargy, not any change in lean body mass or strength, and the question, though it recurs often, is usually settled as a matter of preference alone.
Should RAD140 be taken in the morning or at night?
Outside the published trials, the grounds offered for placing RAD-140 morning or night concern sleep and daytime energy, not how well the compound acts. RAD140 is described as administered at the following hours:
in the morning about as often as at night;
at a morning hour, preferred on the reasoning that nothing is then freshly absorbed at bedtime;
in the evening or just before sleep, with tiredness given as the reason for the move in some accounts;
in the early evening, a few hours before bed, in a few accounts.
Outside the trial record the morning hour is paired in one instance with black coffee, and a greater sense of well-being is attributed to the pairing. These preferences contradict one another, rest on single accounts, and have never been set against a measured outcome.
Should RAD140 be taken with or without food?
RAD140 is generally held to be absorbed whether or not food is present, because orally active selective androgen receptor modulators are commonly described as reaching the circulation in either state, and food is widely understood to slow absorption more often than it alters total exposure. A shift of an hour or two in absorption is therefore held to matter little to the concentration reached under daily administration, given an elimination half-life of nearly two days rather than hours. No food-effect study appears among this article’s sources, so the reasoning rests on the SARM class and not on a measurement of this compound.
When to take RAD140 and MK-677, and at the same time or apart?
Beyond the trial data, the RAD140 and MK-677 stack is described as administered either at the same hour or at separate hours, and the case for separating them rests on the increase in appetite and the drowsiness attributed to MK-677, a growth hormone secretagogue rather than an androgen receptor ligand, never on any effect attributed to RAD140. Appetite and sleep are the grounds, not any measured difference in how either compound engages its receptor.
In those accounts the arrangements described for RAD140 with MK-677, and the further questions the pairing raises, are these (the second compound is listed as MK-677 for sale for laboratory research, with batch identification and purity data for each lot):
both administered together at the same morning hour;
the two apart, with RAD140 in the morning and MK-677 moved to the night;
whether administration of the two begins on the same day or one is staggered behind the other;
whether administering both together in the morning affects absorption.
How long does RAD140 take to kick in?
RAD140 needs anything from days to weeks, in descriptions beyond the trials, to produce a noticeable change, so the question “when does RAD 140 kick in?” has no single answer: some accounts place a first effect within days, many in the first fortnight, others not before several weeks, and the earliest of those impressions are the most contested.
Accounts outside the published studies offer four explanations. The first two account for early impressions; the last two start from the pharmacology and account for little change at the outset:
the placebo effect, an improvement that arises from expectation rather than from pharmacology, to which early impressions are frequently attributed;
water retention together with glycogen, a carbohydrate reserve of skeletal muscle that binds water, since both can alter body weight and appearance within days;
a slow climb of plasma concentrations, held to rise over the first week or two before reaching steady state, so that little is expected at the outset;
a brief exposure, held on the same premise to be unable to produce a change of any size, because such a change is held to arrive only in the later weeks.
Outside the published trials, RAD140 is also described as producing no perceptible change within the first week, and whether that delay is usual is a recurring question about how quickly RAD 140 does its work. Hardest to assess of all are the claims of visible change in lean body mass and of change in strength, the photographic and self-measured RAD 140 before and after material: self-assessed and uncontrolled, with no blinding, no baseline measurement, no comparison group and no record of what the preparation contained.
When suppression is described to begin
Hormone suppression is placed early among the effects described outside the trials, a fall in endogenous testosterone production that follows sustained stimulation of the androgen receptor, with signs within the first weeks; blood markers are described as still low weeks after exposure ended, and the length of the half-life is the reason usually given. Beyond the trial data, one question on recovery after RAD140 returns repeatedly without a settled answer, how soon that fall becomes measurable once the compound is withdrawn. All of this is description, and it stands apart from the SHBG and PSA changes measured in the phase 1 trial, which were recorded during treatment rather than afterwards.
Will RAD raise your blood pressure?
RAD 140 is generally held to be capable of raising blood pressure, though no controlled human study has measured the effect directly. The view of RAD140 and the heart rests on the SARM class: selective androgen receptor modulators are commonly described as acting on androgen receptors in cardiac and vascular tissue, an action widely understood to be able to thicken vascular smooth muscle, add to cardiovascular strain, and lower HDL cholesterol, the fraction associated with lower cardiovascular risk.
Beyond the class, isolated published case reports link RAD140 itself with myocarditis and arterial thrombosis, while the class as a whole is linked more broadly with hypertension. Those findings rest on single case reports or class-wide inferences, and one animal study pointed instead to better cardiac function, so the cardiovascular profile of RAD140 is still regarded as poorly characterised rather than established.
How long until it is fully cleared after the last dose?
Not within a day. On the elimination half-life measured in the trial, the plasma concentration of RAD140 halves only about every two days, so the better part of a week passes before no more than a small fraction remains in circulation. Clearance from plasma and detectability in urine are separate questions, and the urinary work answers the second.
The micro-dose excretion studies in healthy male volunteers analysed urine by liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-HRMS/MS), a pairing that first separates compounds and then weighs their fragments precisely, and set out elimination profiles and detection times for the intact drug and for six metabolites, the products formed when a compound is chemically altered in the body. That is what lets anti-doping laboratories running drug tests for RAD 140 distinguish contamination from intentional administration.
The same studies examined metabolite ratios for their power to estimate the dose administered. Neither dataset yields a clearance time outside its own range, because the trial’s figure comes from patients with advanced cancer at pharmacological doses while the urinary profiles come from micro-doses in a handful of volunteers.
A half-life near two days says nothing about liver tissue: in the one published case that fixes a timeline, drug-induced liver injury declared itself weeks into exposure and receded only over a further period after it ended, a course set out in the liver article.
[Figure 4. RAD140 in urine after micro-doses. Urinary RAD140 in healthy male volunteers after one 50 µg micro-dose (a) and after five daily micro-doses (b): concentrations peaked early and fell to near zero over about two and three weeks, at doses far below the trial’s; not a plasma half-life.]
Washout times described in discussions
Accounts outside the published studies describe washout estimates for RAD140 that run from a few days to well beyond a week. Some come from a SARMs half-life calculator counting successive half-lives until the remaining plasma concentration is judged negligible, others rest on the assumption that a larger administered dose must take proportionally longer to be eliminated, and a third set concedes that the figures are guesswork. The estimates disagree largely because they start from different half-life values, and only one of those values rests on a human measurement.
Timing measured in the trial cannot apply to a preparation that holds less than its label claims or none at all, which laboratory checks of products labelled testolone often found, so in those accounts the testing evidence decides what counts as legit RAD 140.
In those accounts the same doubt reaches every compound, and the same documentation covers all our other SARMs for sale.
Weeks of daily RAD140 in the mouse studies
Both mouse studies measured outcomes only after weeks of daily administration, so neither can date the onset of an effect. In the first, older C57BL/6 mice, 21 males and 15 females aged 23.7 to 25.5 months, received 5 mg/kg/day for six weeks, and their frailty index stayed unchanged; the treated males nevertheless preserved lean body mass and bone mineral density and showed lower serum concentrations than controls of interleukin-6, a circulating signalling protein used as a marker of inflammation, while the treated females showed none of these effects and grip strength and fat mass were unaffected in both sexes.
The second study points the other way. In young and adult female mice given 5 mg/kg for ten weeks, frailty status and mortality risk rose rather than fell, strength did not increase, and the young animals showed reduced adaptive potential. Neither design logged the day on which an effect emerged, so neither bears on onset, and doses per kilogram in mice do not convert into human doses.
RAD140 outside medicine: no licence and a ban in sport
The World Anti-Doping Agency (WADA), which sets the prohibited list for sport, bans RAD140 for athletes at all times, and no regulator has approved the compound for clinical use; it has been studied in humans only as an investigational agent, as in the breast-cancer trial. Every half-life and timing figure in this article therefore comes from research data rather than from the label of a licensed product, and because no such label exists, none of those figures can be checked against a licensed source.
Limits of the evidence on RAD140 half-life and timing
One human trial supplies the only measured half-life, in heavily pretreated postmenopausal women with metastatic breast cancer across three once-daily dose levels, and neither that population nor that dose range matches the conditions described outside the published trials. The human urinary data come from micro-doses in a small number of healthy male volunteers, which limits what they say about larger exposures; the mouse studies recorded outcomes only after six and ten weeks of daily administration and yield no onset curve; and the product analyses show that a label may not describe what a preparation contains at all. A measured half-life presupposes a compound of known content, which is why batch identification and purity data accompany each lot of our RAD-140 Testolone research compound.
Several questions rest on description alone. No published study among this article’s sources has measured any of the following:
a best time of day for administration;
its relation to sleep and tiredness;
the interval before a change appears;
the onset of hormone suppression;
washout times;
the pairing of RAD140 with MK-677 and other compounds.
Frequently asked questions
Is there a best time to take the SARM?
The SARM RAD140 is described, outside the published trials, as having no single best hour, and the pattern named most often is one administration a day at whatever hour is most convenient to hold. The grounds offered for one hour over another concern sleep and daytime energy, not the size of any effect, and nothing in the human data identifies an optimal hour.
When should RAD140 be taken?
Outside the trial record, RAD140 is described as administered once daily, placed in the morning or the evening by preference and then held at a consistent hour. The phase 1 trial that measured the half-life also gave the compound once a day (the only schedule with human data behind it), and no published work compares one hour of the day against another.
Does the time of day matter, morning or night?
The time of day is described, outside the published trials, as mattering little, because the compound is held to persist for days rather than hours. Where a difference is described, it concerns sleep quality, daytime tiredness or mood at a given hour rather than any change in lean body mass or strength, and those impressions contradict one another and rest on single accounts.
When to take RAD140 with MK-677?
Outside the trial record, RAD140 and MK-677 are described sometimes as administered together in the morning and sometimes as separated, with MK-677 moved to the night because of the appetite increase and drowsiness attributed to it. In either arrangement the reasoning concerns appetite and sleep rather than the RAD 140 half life or how either compound engages its receptor, and no published study has compared the two arrangements.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In which group of people was the only human half-life of RAD140 measured?
Healthy adult male volunteers in a urine-based study
Postmenopausal women with advanced breast cancer ✓
Older men with age-related loss of muscle mass
Young athletes tested under anti-doping rules
The one human trial found a half-life of about 44.7 hours in heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, not in healthy men.
What course did liver injury follow in the published RAD-140 case report?
Hepatocellular injury that worsened after the product was stopped
Fatty liver change that appeared within the first few days
Cholestatic injury that resolved once the product was stopped ✓
Cholestatic injury that went on for months after it was stopped
A 24-year-old man developed cholestatic liver injury weeks into exposure, with bilirubin peaking at 38.5 mg/dL, and both symptoms and injury resolved after the agent was withdrawn.
What did the 2025 analysis of SARM supplements bought online in Slovakia find?
Nearly all held the named SARM at its labelled amount
Almost half did not contain the SARM named on the label ✓
Most held the named SARM but at a lower amount than labelled
About one in ten held a different SARM from the one labelled
Of 16 products, the declared SARM was confirmed in only 9, and testolone was the compound most often missing from products that listed it.
What did six weeks of RAD140 do in older male mice?
Raised grip strength and lowered fat mass, with frailty reduced
Raised frailty status and mortality risk compared with controls
Changed nothing in body composition or inflammation markers
Kept lean mass and bone density, while frailty stayed unchanged ✓
Treated older males kept lean mass and bone mineral density and had lower interleukin-6, yet their frailty index did not change, and females showed none of these effects.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
No published study has tested PCT for RAD 140, and a case report records suppressed testosterone normalising once supplements containing it were stopped.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD 140 half life: the trial figure, timing and onset
By Laura Walker, PhD · Reviewed by Elizabeth Hyams
Published · Updated · 21 min read
The RAD 140 half life in brief
The RAD 140 half life measured in the one human trial is about 44.7 hours. That one number is the whole human record on timing: the trial recorded no onset, and descriptions outside the published studies place the first noticeable changes within days in some accounts and only after several weeks in others.
A half-life is how long the plasma concentration of RAD140 takes to fall by half, and this one is the reason the trial administered the compound once daily. The women in that trial had advanced breast cancer, not the profile of a healthy man, so the figure may not carry over exactly; any figure quoted for testolone outside the trial record traces back to that single measurement, and since no second human study has reported the value, every question of schedule in this article turns on one number.
This article sets out the trial’s measurement, the consequences of such a half-life for once-daily administration and for clearance, and beside them what is described outside the trials about time of day, food, onset, and the pairing of RAD140 with MK-677 (ibutamoren), a growth hormone secretagogue. Drug-test detection windows, and any schedule for a reader to follow, stay out.
Why does one trial carry so much weight? Because of where RAD140 was tested. It is an orally administered selective androgen receptor modulator (SARM), a class named by analogy with the selective oestrogen receptor modulators, and the RAD 140 mechanism of action is that of a synthetic ligand of the androgen receptor, the protein inside cells that androgens act on. A compound on the usual licensing route has its pharmacokinetics, how it is absorbed, distributed and cleared over time, measured first in healthy volunteers; RAD140 went straight into oncology, as a candidate treatment for a tumour expressing that receptor, so its figures were measured in patients, and they carry the marks of that setting.
How the half-life was measured in the first human trial
The first-in-human phase 1 study of RAD140 (vosilasarm in the breast cancer trials) put its elimination half-life, the time plasma concentrations take to halve once absorption is complete and clearance dominates, at nearly two days, the value in hours that the figure below gives. At that earliest stage of testing in humans, safety and the handling of a compound count for more than efficacy, and the RAD 140 study set out to characterise safety, tolerability, the pharmacokinetic profile and the maximum tolerated dose (the highest dose whose toxicity a protocol accepts). The half-life came out of the third of those aims, pharmacokinetics.
The study opened with a dose escalation on a 3 + 3 design, which fills each dose level with a cohort of patients and adds a second cohort if toxicity appears before the next level opens, and a pharmacokinetic expansion cohort then brought the enrolment of women to the total the figure below shows. Of everything the study reported, the hours RAD-140 needed to fall to half its plasma concentration mattered most to the protocol, because that figure largely sets a dosing interval, and at nearly two days the interval is long for an orally administered agent.
Was the half-life measured in healthy men or in cancer patients?
In cancer patients. The half-life of RAD140 comes from postmenopausal women, whose number the table below gives, with ER+/HER2- metastatic breast cancer (a tumour that carries oestrogen receptors, lacks HER2 amplification and has spread beyond the breast); 21 of them were androgen receptor (AR)-positive, and all had received several earlier lines of treatment.
Healthy adult male volunteers appear in one human study among this article’s sources, and it is of a different kind: a micro-dose excretion study, which administers a dose far below a pharmacological one and follows its appearance in urine, repeated several times with a small group of volunteers each time, as the table sets out. A design that samples urine rather than plasma yields elimination profiles and detection times, not a half-life. The trial’s value therefore belongs to the oncology population and its dose range, and it stands as the best human measure available rather than a figure established in healthy men.
The human data on RAD140 compared
Is once a day enough given the half-life?
Enough for the trial, which gave each of its three dose levels once daily. The arithmetic is the RAD140 half-life’s: at nearly two days, much of one day’s dose is still circulating when the next arrives, so concentrations climb over the first days until absorption and clearance balance, which is steady state, and from then on they fluctuate less within each day than those of a compound with a short elimination half-life would. Dividing the daily dose was never examined; the published trial summary describes no schedule other than once-daily administration at every dose level.
Doses and the dose limit in the first trial
Enrolment across the three once-daily dose levels was uneven: six women were on 50 mg, thirteen on 100 mg, and only three reached 150 mg, above the maximum tolerated dose of 100 mg a day. Toxicity, not any shortage of activity, closed the 150 mg level. Most of the human exposure therefore sits at the middle level, and the pharmacokinetic figure rests chiefly on 100 mg rather than on the range as a whole. These RAD140 doses went to patients with advanced cancer under hospital monitoring, and any reading of them has to start there.
The toxicity recorded across those levels falls into two groups of treatment-emergent adverse events, those arising during treatment whatever their cause. The hepatic group is the trial’s evidence on RAD140 liver toxicity: aspartate aminotransferase (AST) and its companion alanine aminotransferase (ALT), two enzymes measured in blood as markers of hepatocellular injury, rose more often than any other event, AST in the larger share of patients, and total bilirubin rose in a smaller share.
The gastrointestinal and nutritional group, vomiting, dehydration, decreased appetite and decreased body weight, each occurred as often as the bilirubin rise, so food consumption and weight were affected about as often as the clearance of bile; the figure below gives the share of patients for each event. Severity sharpens the picture: events of grade 3 or 4 affected 72.7% of patients, and among them AST and ALT elevations and hypophosphataemia (a low concentration of phosphate in blood) each reached 22.7%, which puts the two liver enzymes among the severe events as well.
Signs of androgen receptor engagement in trial participants
Two blood markers served the trial as surrogates for engagement of the androgen receptor: serum sex hormone-binding globulin (SHBG) fell in every patient tested, and prostate-specific antigen (PSA) rose in most of those tested, as the figure below shows. Paired tumour biopsies taken before and during treatment then confirmed the engagement directly.
Clinical outcomes over the same period were modest, a clinical benefit rate of 18.2% at 24 weeks (the share of patients free of progression at that point) and a median progression-free survival of 2.3 months (the time by which half the patients had progressed or died). One thing the summary withholds matters for this article: it gives the share of patients whose markers moved, not the week when they moved, so onset in humans rests on these markers and on what is described outside the trials.
When is the best time to take RAD140?
In descriptions beyond the trials, no single best time is named for RAD140. The patterns described are these:
In those accounts the hour chosen makes little difference to anything but sleep and alertness, because the compound is held to persist over days rather than hours, and the practical questions that follow concern a late or missed administration and how a consistent hour can be kept when the time of waking varies. Such accounts of RAD 140 experience are individual and uncontrolled, collected and compared here rather than read as measurements; nothing in the human trial data identifies an optimal hour.
Does it matter what time of day RAD140 is taken?
Among the effects described outside the trials, the time of day at which RAD140 is administered is held to matter little, and the reason given is how long the compound is said to remain in circulation. In descriptions beyond the trials the differences that are named concern sleep, mood at a particular hour or the daytime tiredness described as RAD 140 lethargy, not any change in lean body mass or strength, and the question, though it recurs often, is usually settled as a matter of preference alone.
Should RAD140 be taken in the morning or at night?
Outside the published trials, the grounds offered for placing RAD-140 morning or night concern sleep and daytime energy, not how well the compound acts. RAD140 is described as administered at the following hours:
Outside the trial record the morning hour is paired in one instance with black coffee, and a greater sense of well-being is attributed to the pairing. These preferences contradict one another, rest on single accounts, and have never been set against a measured outcome.
Should RAD140 be taken with or without food?
RAD140 is generally held to be absorbed whether or not food is present, because orally active selective androgen receptor modulators are commonly described as reaching the circulation in either state, and food is widely understood to slow absorption more often than it alters total exposure. A shift of an hour or two in absorption is therefore held to matter little to the concentration reached under daily administration, given an elimination half-life of nearly two days rather than hours. No food-effect study appears among this article’s sources, so the reasoning rests on the SARM class and not on a measurement of this compound.
When to take RAD140 and MK-677, and at the same time or apart?
Beyond the trial data, the RAD140 and MK-677 stack is described as administered either at the same hour or at separate hours, and the case for separating them rests on the increase in appetite and the drowsiness attributed to MK-677, a growth hormone secretagogue rather than an androgen receptor ligand, never on any effect attributed to RAD140. Appetite and sleep are the grounds, not any measured difference in how either compound engages its receptor.
In those accounts the arrangements described for RAD140 with MK-677, and the further questions the pairing raises, are these (the second compound is listed as MK-677 for sale for laboratory research, with batch identification and purity data for each lot):
How long does RAD140 take to kick in?
RAD140 needs anything from days to weeks, in descriptions beyond the trials, to produce a noticeable change, so the question “when does RAD 140 kick in?” has no single answer: some accounts place a first effect within days, many in the first fortnight, others not before several weeks, and the earliest of those impressions are the most contested.
Accounts outside the published studies offer four explanations. The first two account for early impressions; the last two start from the pharmacology and account for little change at the outset:
Outside the published trials, RAD140 is also described as producing no perceptible change within the first week, and whether that delay is usual is a recurring question about how quickly RAD 140 does its work. Hardest to assess of all are the claims of visible change in lean body mass and of change in strength, the photographic and self-measured RAD 140 before and after material: self-assessed and uncontrolled, with no blinding, no baseline measurement, no comparison group and no record of what the preparation contained.
When suppression is described to begin
Hormone suppression is placed early among the effects described outside the trials, a fall in endogenous testosterone production that follows sustained stimulation of the androgen receptor, with signs within the first weeks; blood markers are described as still low weeks after exposure ended, and the length of the half-life is the reason usually given. Beyond the trial data, one question on recovery after RAD140 returns repeatedly without a settled answer, how soon that fall becomes measurable once the compound is withdrawn. All of this is description, and it stands apart from the SHBG and PSA changes measured in the phase 1 trial, which were recorded during treatment rather than afterwards.
Will RAD raise your blood pressure?
RAD 140 is generally held to be capable of raising blood pressure, though no controlled human study has measured the effect directly. The view of RAD140 and the heart rests on the SARM class: selective androgen receptor modulators are commonly described as acting on androgen receptors in cardiac and vascular tissue, an action widely understood to be able to thicken vascular smooth muscle, add to cardiovascular strain, and lower HDL cholesterol, the fraction associated with lower cardiovascular risk.
Beyond the class, isolated published case reports link RAD140 itself with myocarditis and arterial thrombosis, while the class as a whole is linked more broadly with hypertension. Those findings rest on single case reports or class-wide inferences, and one animal study pointed instead to better cardiac function, so the cardiovascular profile of RAD140 is still regarded as poorly characterised rather than established.
How long until it is fully cleared after the last dose?
Not within a day. On the elimination half-life measured in the trial, the plasma concentration of RAD140 halves only about every two days, so the better part of a week passes before no more than a small fraction remains in circulation. Clearance from plasma and detectability in urine are separate questions, and the urinary work answers the second.
The micro-dose excretion studies in healthy male volunteers analysed urine by liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-HRMS/MS), a pairing that first separates compounds and then weighs their fragments precisely, and set out elimination profiles and detection times for the intact drug and for six metabolites, the products formed when a compound is chemically altered in the body. That is what lets anti-doping laboratories running drug tests for RAD 140 distinguish contamination from intentional administration.
The same studies examined metabolite ratios for their power to estimate the dose administered. Neither dataset yields a clearance time outside its own range, because the trial’s figure comes from patients with advanced cancer at pharmacological doses while the urinary profiles come from micro-doses in a handful of volunteers.
A half-life near two days says nothing about liver tissue: in the one published case that fixes a timeline, drug-induced liver injury declared itself weeks into exposure and receded only over a further period after it ended, a course set out in the liver article.
Washout times described in discussions
Accounts outside the published studies describe washout estimates for RAD140 that run from a few days to well beyond a week. Some come from a SARMs half-life calculator counting successive half-lives until the remaining plasma concentration is judged negligible, others rest on the assumption that a larger administered dose must take proportionally longer to be eliminated, and a third set concedes that the figures are guesswork. The estimates disagree largely because they start from different half-life values, and only one of those values rests on a human measurement.
Timing measured in the trial cannot apply to a preparation that holds less than its label claims or none at all, which laboratory checks of products labelled testolone often found, so in those accounts the testing evidence decides what counts as legit RAD 140.
In those accounts the same doubt reaches every compound, and the same documentation covers all our other SARMs for sale.
Weeks of daily RAD140 in the mouse studies
Both mouse studies measured outcomes only after weeks of daily administration, so neither can date the onset of an effect. In the first, older C57BL/6 mice, 21 males and 15 females aged 23.7 to 25.5 months, received 5 mg/kg/day for six weeks, and their frailty index stayed unchanged; the treated males nevertheless preserved lean body mass and bone mineral density and showed lower serum concentrations than controls of interleukin-6, a circulating signalling protein used as a marker of inflammation, while the treated females showed none of these effects and grip strength and fat mass were unaffected in both sexes.
The second study points the other way. In young and adult female mice given 5 mg/kg for ten weeks, frailty status and mortality risk rose rather than fell, strength did not increase, and the young animals showed reduced adaptive potential. Neither design logged the day on which an effect emerged, so neither bears on onset, and doses per kilogram in mice do not convert into human doses.
RAD140 outside medicine: no licence and a ban in sport
The World Anti-Doping Agency (WADA), which sets the prohibited list for sport, bans RAD140 for athletes at all times, and no regulator has approved the compound for clinical use; it has been studied in humans only as an investigational agent, as in the breast-cancer trial. Every half-life and timing figure in this article therefore comes from research data rather than from the label of a licensed product, and because no such label exists, none of those figures can be checked against a licensed source.
Limits of the evidence on RAD140 half-life and timing
One human trial supplies the only measured half-life, in heavily pretreated postmenopausal women with metastatic breast cancer across three once-daily dose levels, and neither that population nor that dose range matches the conditions described outside the published trials. The human urinary data come from micro-doses in a small number of healthy male volunteers, which limits what they say about larger exposures; the mouse studies recorded outcomes only after six and ten weeks of daily administration and yield no onset curve; and the product analyses show that a label may not describe what a preparation contains at all. A measured half-life presupposes a compound of known content, which is why batch identification and purity data accompany each lot of our RAD-140 Testolone research compound.
Several questions rest on description alone. No published study among this article’s sources has measured any of the following:
Frequently asked questions
Is there a best time to take the SARM?
The SARM RAD140 is described, outside the published trials, as having no single best hour, and the pattern named most often is one administration a day at whatever hour is most convenient to hold. The grounds offered for one hour over another concern sleep and daytime energy, not the size of any effect, and nothing in the human data identifies an optimal hour.
When should RAD140 be taken?
Outside the trial record, RAD140 is described as administered once daily, placed in the morning or the evening by preference and then held at a consistent hour. The phase 1 trial that measured the half-life also gave the compound once a day (the only schedule with human data behind it), and no published work compares one hour of the day against another.
Does the time of day matter, morning or night?
The time of day is described, outside the published trials, as mattering little, because the compound is held to persist for days rather than hours. Where a difference is described, it concerns sleep quality, daytime tiredness or mood at a given hour rather than any change in lean body mass or strength, and those impressions contradict one another and rest on single accounts.
When to take RAD140 with MK-677?
Outside the trial record, RAD140 and MK-677 are described sometimes as administered together in the morning and sometimes as separated, with MK-677 moved to the night because of the appetite increase and drowsiness attributed to it. In either arrangement the reasoning concerns appetite and sleep rather than the RAD 140 half life or how either compound engages its receptor, and no published study has compared the two arrangements.
Check what you remember
4 questions on this article; the right answer is marked.
The one human trial found a half-life of about 44.7 hours in heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, not in healthy men.
A 24-year-old man developed cholestatic liver injury weeks into exposure, with bilirubin peaking at 38.5 mg/dL, and both symptoms and injury resolved after the agent was withdrawn.
Of 16 products, the declared SARM was confirmed in only 9, and testolone was the compound most often missing from products that listed it.
Treated older males kept lean mass and bone mineral density and had lower interleukin-6, yet their frailty index did not change, and females showed none of these effects.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
RAD140 dose: what the trials gave and the evidence covers
No RAD140 dose is approved: its dose-finding trial gave 50, 100 or 150 mg daily in breast cancer, and a later vosilasarm study gave 10 mg twice daily.
Ostarine course length: trial durations and what is reported
ostarine cycle length in the enobosarm trials ran 86 to 147 days once daily, while published liver injury cases followed about six weeks of exposure.
RAD 140 suppression and recovery: what the evidence shows
No published study has tested PCT for RAD 140, and a case report records suppressed testosterone normalising once supplements containing it were stopped.